Understand An Area in Depth. Our Reports Delve into the Real Issues Affecting Your Performance in Each Area.

Our team produce a number of pharmaceutical market reports on a variety of topics relevant to pharmaceutical marketers. Our reports mainly focus on measurement of the return on investment from sales and marketing activities to determine how to grow the brands sales, market share and profit and outline pitfalls in many of the current ways the industry is currently doing things.

While not as comprehensive as the Eularis analytics tools, our market reports give a strong insight on the state of the art in the industry today in specific areas.

---Current In-Depth Reports Available---

Topic Area: Pharmaceutical Marketing Return on Investment (ROI)

1. Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line

Written by Dr Andree Bates, this report analyses the different methods being used by the pharmaceutical industry such as ROI, promotional response models, econometrics and predictive algorithms and the pros and cons of the different approaches.
Publication Date: 1 March 2007
Pages: 86
To read about this report, or to view sample pages, or to buy, please go to

Pharma Marketing ROI

2. The Nine Secrets Every Pharmaceutical Marketer Needs to Know to Thrive in 2008

Written by Dr Andree Bates, this report analyses the key ways the pharmaceutical marketer needs to change their marketing approach to deal with the current pharma market changes for success in 2008 and beyond. Includes 6 case studies.
Publication Date: 6 Feb 2008
Pages: 23
To request this report, please go to

Eularis Front Page Sign-Up

3. Eularis Conference Review: Pharma Marketing Europe

Written by Dr Andree Bates, this report covers all the presentations at the eyeforpharma 7th Annual European Pharmaceutical Marketing Congress in Barcelona, Spain October 2007.
Publication Date: 1 November 2007
Pages: 21
To request this report, please go to

Pharma Marketing Europe Congress Sign-Up

Topic Area: Pharmaceutical Sales Force Effectiveness Metrics and Return on Investment (ROI)

1. Pharmaceutical Sales Force Effectiveness Metrics: Are You Measuring the Wrong Things?

Sales force represents the largest spend in sales and marketing and yet, study after study show that the returns gained from this spend is not particularly strong. Dr Andree Bates uses market data and case studies as evidence to argue the case for new metrics that show real sales force effectiveness than leads to market share gains. This report dissects current SFE metrics and their limitations, for the pharmaceutical industry in the United States, Europe and Japan. The report then discusses appropriate metrics to solve these problems, and demonstrates implementation methods and issues and shows real case studies of these newer metrics in use. Sales force effectiveness is a difficult concept to measure, but doing so can push pharmaceutical companies past todays hurdles and into increased productivity and sales.
Publication Date: 5 November 2007
Pages: 55
To read about this report, or to view sample pages, or to buy, please go to

Pharma Industry SFE

2. Pharma Sales World 2007: Advanced Sales Force Remodelling Strategies in a Multi-Channel Environment

Pharma Sales World 2007: Advanced Sales Force Remodelling Strategies in a Multi-Channel Environment not only reminded attendees of the significant challenges the industry faces today, but also detailed many of the industrys attempts at fixing these problems while introducing new complexities, particularly with sales force effectiveness (SFE) programmes.
Publication Date: 31 January 2008
Pages: 22
To read about this report, or to view sample pages, or to buy, please go to

Pharma Sales World 2007 Report

Topic Area: Patient Adherence Programs Return on Investment, Patient Compliance Programs Return on Investment (ROI)

1. Releasing the Hidden Value from Patient Compliance/Adherence Programs

Costing the global pharmaceutical industry an estimated $30 billion per year and causing an estimated 125,000 deaths per year in the United States, patient non-adherence is a looming issue in the healthcare industry. Dr. Andree Bates has responded to this problem with a new report, available today, titled, Releasing the Hidden Value from Patient Compliance/Adherence Programs This report analyzes the underlying barriers to patient compliance and studies how pharmaceutical companies can implement successful adherence programs that will improve patient care while also increasing profitability.
Publication Date: 5 February 2008
Pages: 55
To read about this report, or to view sample pages, or to buy, please go to

Pharma Industry Patient Adherence ROI

Topic Area: Generic Defense Strategies for Branded Pharma

1. How to Plan an Effective Generics Defense Strategy: Planning, Tactics and Implementation

More than 60% of all prescriptions filled in the US are for generic drugs, and more than $60 billion worth of drugs face US patent expiration by 2011. The increase in patent expiries and a poor pipeline, and an unfavorable legal and regulatory environment, has caused companies to reassess the most effective strategies to deliver the maximum returns from their drugs portfolio. This report outlines the key strategies companies use to build a counter-generics strategy (such as new formulations, new indications, Rx to OTC switch, authorized generics, mergers and acquisitions etc) and also outlines key generics companies and the strategies they are using to capture an even stronger share of the drugs market. The report analyzes the most effective legal, reformulation and marketing strategies to counteract the generic threat and details the benefits of an integrated brand defense strategy. It also outlines how to use analytics to test how effective your generics defense strategy will be and how it will hold up to the threat. Europe, US and Japan situations are analyzed in-depth. Use this report to ensure that you have selected the most effective strategies for your brand and market. These strategies will help you grow market share and enable you to extend your brands lifecycle despite increasing generic competition.
Publication Date: July 2008
Pages: 66
To read about this report, or to view sample pages, or to buy, please go to

How to Plan an Effective Generics Defense Strategy: Planning, Tactics and Implementation

Topic Area: Online Pharma Marketing, eMarketing and eDetailing

1. eDetailing: A Strategic Analysis of Implementation and ROI: Revised 2008 Edition

In eDetailing; A Strategic Analysis of Implementation and ROI, Eularis provides a recent (2008) comprehensive insight into the subject of pharmaceutical detailing using the Internet. As the vast majority of eDetailing pilots have taken place in the US, the report looks at the likelihood of European pharmaceutical companies following suit. Return on Investment (ROI) is also important. This report discusses the available evidence on ROI and illustrates some models that can be used. Eularis made extensive efforts to provide the most insightful information about this fast moving subject. This involves;
*Surveying over 200 general practitioners about their attitudes to pharmaceutical sales representatives and eDetailing,
*Carefully assessing the current regulatory environment in the UK and how eDetailing programmes could be affected,
*Sourcing case studies of ROI from the USA,
*Extensive research into vendor companies and their market position,
*Strategic considerations and advice.
Publication Date: November 2008
Pages: 84
To pre-order this report, please email

Peter Llewellyn today for more information.

2. eDetailing: A Strategic Analysis of Implementation and ROI: 2001

In eDetailing; A Strategic Analysis of Implementation and ROI, Eularis provides a comprehensive insight into the subject of pharmaceutical detailing using the Internet as it was in 2001. As the vast majority of eDetailing pilots have taken place in the US, the report looks at the likelihood of European pharmaceutical companies following suit. Return on Investment (ROI) is also important. This report discusses the available evidence on ROI and illustrates some models that can be used. Eularis made extensive efforts to provide the most insightful information about this fast moving subject. This involves;
*Surveying over 200 general practitioners about their attitudes to pharmaceutical sales representatives and eDetailing,
*Carefully assessing the current regulatory environment in the UK and how eDetailing programmes could be affected,
*Sourcing case studies of ROI from the USA,
*Extensive research into vendor companies and their market position,
*Strategic considerations and advice.
Publication Date: March 2001
Pages: 84
To request this report, please go to

Eularis Report Sign-Up

3. Online Marketing and eDetailing

In-depth report from the eyeforpharma conference, Berlin, 8-9 May 2006. After a decade of e-marketing and e-detailing, which included much hype and expectation, the dust is beginning to settle on a phase of more realistic expectations and approaches.This reports shows where we are now.
Publication Date: 28 July 2006
Pages: 24
To read about this report, or to view sample pages, or to buy, please go to

Online Marketing and eDetailing Report

Client Quotes.

Client Quote on 'Navigating the eDetailing maze for effective ROI' report:

'This was simply the most comprehensive and insightful report on e-detailing available. It helped us enormously.'

Len Starnes, Head of European E-Marketing, Schering AG